IQVIA Announces Connected Intelligence™

Rhea-AI Summary

IQVIA announced its innovative approach, Connected Intelligence, aimed at enhancing insights and decision-making in the life sciences sector. This strategy integrates IQVIA’s extensive healthcare data, advanced analytics, and technologies to facilitate faster drug development. Key initiatives include:

• Accelerating over 350 clinical research studies for COVID-19.
• Supporting 60 decentralized clinical trials in 40 countries.
• Linking real-world data for disease understanding and drug discovery.

IQVIA aims to improve societal health outcomes through innovation and significant investments in the healthcare ecosystem.

Positive

• Introduction of Connected Intelligence to enhance decision-making in life sciences.
• Over 350 ongoing clinical studies aimed at COVID-19 treatments.
• Involvement in 60 decentralized trials across 40 countries with 170,000 patients.
• Use of big data and analytics for better disease understanding and drug discovery.

Negative

• None.

IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster.

Connected Intelligence brings together IQVIA’s unique portfolio of capabilities to create intelligent connections across its unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to speed the development and commercialization of innovative medicines that improve patient lives. Connected Intelligence provides new levels of value across clinical, compliance and commercial stakeholders within pharma, med tech, payers, providers, and government organizations.

IQVIA’s Connected Intelligence in action includes:

• Connecting data, analytics, and services to accelerate more than 350 ongoing clinical research studies to find treatments and novel vaccines for COVID-19
• Deploying innovative technologies across 60 ongoing decentralized clinical trials spanning 40 countries utilizing IQIVA’s virtual capabilities to enroll more than 170,000 patients globally
• Bringing together big data, advanced analytics, and healthcare expertise to help industry professionals better understand diseases, their spread and outcomes
• Accelerating drug discovery by creating intelligent connections across private companies, government agencies, and university researchers
• Linking real world data and healthcare expertise to enable contact tracing and COVID-19 testing protocols to reveal novel disease insights

The world is counting on the healthcare industry for innovations and scientific breakthroughs to improve societal health. IQVIA, recognizing that the healthcare industry needs to increase agility and accelerate results, has made significant investments and commitment to the healthcare ecosystem, and has the global scale and experience to deliver a completely new approach to moving healthcare forward.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 72,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005564/en/

FAQ

What is IQV's Connected Intelligence?

Connected Intelligence is IQVIA's innovative strategy that integrates healthcare data, analytics, and technology to drive insights and expedite drug development.

How many clinical trials is IQV involved in?

IQVIA is currently involved in over 350 ongoing clinical research studies, particularly focusing on COVID-19.

What impact does Connected Intelligence have on drug development?

Connected Intelligence enhances the speed and effectiveness of drug development and commercialization by leveraging comprehensive healthcare data and analytics.

In how many countries are IQV's clinical trials conducted?

IQVIA is conducting decentralized clinical trials in 40 countries.

How many patients are enrolled in IQV's clinical trials?

Over 170,000 patients are currently enrolled in IQVIA's decentralized clinical trials.